


# EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism

Alice Modernelli<sup>1,2#</sup>, Valeria Naponelli<sup>1-3#</sup>, Maria Giovanna Troglio<sup>1</sup>, Martina Bonacini<sup>1</sup>, Ileana Ramazzina<sup>1-3</sup>, Saverio Bettuzzi<sup>1-3\*</sup> and Federica Rizzi<sup>1-3\*</sup>.

<sup>1</sup>Department of Biomedicine, Biotechnology and Translational Research, University of Parma, Via Volturno 39/a, 43125 Parma, Italy; <sup>2</sup>Centre for Molecular and Translational Oncology (COMT), University of Parma, Parco Area delle Scienze 11/a, 43124 Parma, Italy; <sup>3</sup>National Institute of Biostructure and Biosystems (INBB), Viale Medaglie d'Oro 305, 00136 Rome, Italy.

# These authors contributed equally to the article.

\* Corresponding authors: Federica Rizzi, e-mail: federica.rizzi@unipr.it; Saverio Bettuzzi, e-mail: saverio.bettuzzi@unipr.it.



**Supplementary Figure 1 – Dose-response curve of EGCG.** PC3 cells were treated 48 hours with increasing concentrations of EGCG. Percentage of PC3 cell viability was determined by WST-1 assay. Data are expressed as mean  $\pm$  SD of three determinations in triplicate. The dose-response curve was generated and IC<sub>50</sub> value was determined by non-linear regression analysis.